FDA Brief

Warning letters Drugs

FDA warning letter to

Strukmyer LLC dba Strukmyer Medical

High riskIssued Jan 30, 2025Posted Feb 11, 2025Center for Drug Evaluation and Research (CDER)

Strukmyer Medical was cited for current good manufacturing practice violations after FDA found repeated microbial contamination in water used to make OTC drugs.

What happened

FDA inspected the drug manufacturing facility from July 8 to August 1, 2024. The agency found that over 60 times between November 1, 2022 and July 10, 2024, the firm isolated objectionable microorganisms from its water system, which was used as an ingredient to make over-the-counter drug products for wounds and burns. FDA also found inadequate testing of incoming components, inadequate cleaning, and inadequate quality unit oversight.

What FDA found

  1. The firm did not thoroughly investigate repeated harmful microorganism findings in its water system or determine root causes and prevent recurrence.

    21 CFR 211.192
  2. The firm did not test each component lot for identity and conformity and did not validate supplier test results, including failing to test each glycerin lot for diethylene glycol and ethylene glycol.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  3. The firm did not show its cleaning and disinfection removed all contaminants from equipment, because cleaning validation only tested for Gram-negative bacteria.

    21 CFR 211.67(a)
  4. The firm's quality unit did not ensure contract laboratory chemical and microbial test methods were adequately validated or verified.

    21 CFR 211.22(a)
  5. The firm's drug products are adulterated because its manufacturing methods, facilities, or controls did not conform to CGMP.

    FD&C Act section 501(a)(2)(B) [21 U.S.C. 351(a)(2)(B)]

What FDA wants

FDA tells the company to correct the violations promptly and respond in writing within 15 working days with corrective actions, risk assessments, investigations, and remediation plans; FDA also recommends a qualified CGMP consultant.

Who should pay attention

  • brands that buy finished OTC drug products from this contract manufacturer
  • companies using glycerin or other high-risk components in drug products
  • quality teams that oversee contract laboratories and water systems

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. CNC Noodle Corporation

    FDA warned CNC Noodle Corporation that its Hayward, California noodle plant had insanitary conditions, no pathogen or allergen controls, and mislabeled products.

    High risk
  2. USV Private Limited

    FDA warned USV Private Limited that its sterile injectable manufacturing in Daman, India, had aseptic-processing, facility-design and visible-particulate violations.

    High risk
  3. Next Medical Products Company, LLC

    FDA warns Next Medical Products that its ultrasound gels were contaminated and made without required quality controls or clearance.

    High risk
  4. Northland Nuclear Medicine, LLC

    FDA warned Northland Nuclear Medicine in Bismarck, ND, that its PET drugs are adulterated because it failed to investigate microbial contamination and low yields.

    High risk